Brain cancer hope: new drugs tested in major trial
NCT ID NCT02977780
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial is testing several experimental drugs, alone or in combination, for people with newly diagnosed glioblastoma, an aggressive brain cancer. About 460 participants will receive one of the study drugs or standard therapy. The main goal is to see if these new treatments help people live longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Temozolomide, Neratinib, QBS10072S, Abemaciclib, CC-115
What this could lead to
If successful, this trial could identify new drug combinations that extend survival for people with glioblastoma, a hard-to-treat brain cancer.
What could go wrong
This is a mid-stage trial, so results are not yet proven. The drugs may not work better than standard care, and side effects could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic
ACTIVE_NOT_RECRUITINGCleveland, Ohio, 44195, United States
-
Columbia University Medical Center
ACTIVE_NOT_RECRUITINGNew York, New York, 10032, United States
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Huntsman Cancer Institute
ACTIVE_NOT_RECRUITINGSalt Lake City, Utah, 84112, United States
-
Lifespan / Rhode Island Hospital
ACTIVE_NOT_RECRUITINGProvidence, Rhode Island, 02903, United States
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mayo Clinic
ACTIVE_NOT_RECRUITINGRochester, Minnesota, 55905, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UT MD Anderson Cancer Center
COMPLETEDHouston, Texas, 77030, United States
-
University of Alabama at Birmingham
ACTIVE_NOT_RECRUITINGBirmingham, Alabama, 35294, United States
-
University of Pittsburgh Medical Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Virginia Health System
COMPLETEDCharlottesville, Virginia, 22908, United States